keyword
MENU ▼
Read by QxMD icon Read
search

Bioresorbable scaffolds

keyword
https://www.readbyqxmd.com/read/28449432/should-we-reconsider-dual-antiplatelet-therapy-duration-following-bioresorbable-scaffold-angioplasty
#1
EDITORIAL
Dario Buccheri, Giuseppe Caramanno, Salvatore Geraci, Bernardo Cortese
No abstract text is available yet for this article.
March 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28446750/expandable-mg-based-helical-stent-assessment-using-static-dynamic-and-porcine-ex-vivo-models
#2
Youngmi Koo, Tarannum Tiasha, Vesselin N Shanov, Yeoheung Yun
A bioresorbable metallic helical stent was explored as a new device opportunity (magnesium scaffold), which can be absorbed by the body without leaving a trace and simultaneously allowing restoration of vasoreactivity with the potential for vessel remodeling. In this study, developed Mg-based helical stent was inserted and expanded in vessels with subsequent degradation in various environments including static, dynamic, and porcine ex vivo models. By assessing stent degradation in three different environments, we observed: (1) stress- and flow-induced degradation; (2) a high degradation rate in the dynamic reactor; (3) production of intermediate products (MgO/Mg(OH)2 and Ca/P) during degradation; and (4) intermediate micro-gas pocket formation in the neighboring tissue ex vivo model...
April 26, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28440067/real-life-data-regard%C3%A4-ng-acute-procedural-success-and-1-year-clinical-outcome-of-desolve-bioresorbable-scaffolds
#3
Haci Murat Gunes, Tayyar Gokdeniz, Filiz Kizilirmak Yilmaz, Gultekin Gunhan Demir, Ekrem Guler, Gamze Babur Guler, Oğuz Karaca, Beytullah Cakal, Mehmet Onur Omaygenç, Ersin İbişoğlu, Bilal Boztosun
OBJECTIVES: We aimed to evaluate the peri-procedural success of DESolve bio-resorbable scaffolds (BRSs) and analyzed real-life data about major cardiac events during 1-year follow-up. BACKGROUND: There is little information about real-life data of DESolve BRS which is a novel stent technology offering various advantages over drug eluting stents and commonly used in daily cardiology practice. METHODS: We conducted this single-center and non-randomized cross-sectional study from June 2015 through August 2016 in Medipol University Department of Cardiology and included 117 patients undergoing single or multivessel percutaneous coronary interventions (PCI) with novolimus-eluting BRS devices (152 scaffolds) (Elixir Medical Corporation)...
April 25, 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/28438304/thirty-day-outcomes-after-unrestricted-implantation-of-bioresorbable-vascular-scaffold-from-the-prospective-rai-registry
#4
Bernardo Cortese, Alfonso Ielasi, Elisabetta Moscarella, Bruno Loi, Giuseppe Tarantini, Francesco Pisano, Alessandro Durante, Giampaolo Pasquetto, Alessandro Colombo, Gabriele Tumminello, Luciano Moretti, Paolo Calabrò, Pietro Mazzarotto, Attilio Varricchio, Maurizio Tespili, Roberto A Latini, Gianfranco Defilippi, Donatella Corrado, Giuseppe Steffenino
The Absorb biovascular scaffold (BVS) is a bioresorbable, everolimus-eluting scaffold whose data on real-world patients with complex lesions are limited. Short-term follow-up from recent studies point to a higher rate of 30-day thrombosis than observed with drug-eluting stents. We aimed to understand the short-term safety and efficacy of BVS. Registro Absorb Italiano (RAI, ClinicalTrials.gov:NCT02298413) is an Italian, prospective, multicenter registry not funded, whose aim is to investigate BVS performance through a 5-year follow-up of all consecutive patients who have undergone successful implantation of ≥1 BVS in different clinical/lesion subsets...
March 29, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28437245/long-term-outcome-of-a-spontaneous-coronary-artery-dissection-treated-with-a-bioresorbable-scaffold
#5
Nieves Gonzalo, Fernando Macaya, José J Gómez de Diego, Javier Escaned
No abstract text is available yet for this article.
April 25, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28432385/bioresorbable-vascular-scaffolds-in-coronary-chronic-total-occlusions-revascularization-safety-assessment-related-to-struts-coverage-and-apposition-in-6-month-oct-follow-up
#6
Rosa Alba Abellas-Sequeiros, Raymundo Ocaranza-Sanchez, Ramiro Trillo-Nouche, Carlos Gonzalez-Juanatey, Jose Ramon Gonzalez-Juanatey
Beneficial properties of bioresorbable vascular scaffolds (BVS) regarding to vasomotility restoration and no caging of the vessel make them attractive devices in chronic total occlusions (CTO) revascularization. However, more evidence is needed attending to their use in this specific setting. We aim to determine feasibility and safety of BVS use in CTO revascularization attending to struts coverage and apposition, as well as re-stenosis and stent thrombosis (ST) rates. 29 BVS were deployed in 9 CTO lesions revascularization (mean J-CTO score ≥3) with an acute procedural success rate of 100%...
April 21, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/28430908/late-thrombotic-events-after-bioresorbable-scaffold-implantation-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#7
Carlos Collet, Taku Asano, Yosuke Miyazaki, Erhan Tenekecioglu, Yuki Katagiri, Yohei Sotomi, Rafael Cavalcante, Robbert J de Winter, Takeshi Kimura, Runlin Gao, Serban Puricel, Stéphane Cook, Davide Capodanno, Yoshinobu Onuma, Patrick W Serruys
Aims: To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions. Methods and Results: A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model by the Knapp-Hartung method was used to compute odds ratios (OR) and 95% confidence intervals (CI)...
April 18, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28427596/bioresorbable-vascular-scaffolds-a-step-closer-to-the-dream
#8
EDITORIAL
Stephen Ellis
No abstract text is available yet for this article.
April 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28427595/vasomotor-response-to-nitroglycerine-over-5-years-follow-up-after-everolimus-eluting-bioresorbable-scaffold-implantation
#9
Dariusz Dudek, Łukasz Rzeszutko, Yoshinobu Onuma, Yohei Sotomi, Rafał Depukat, Susan Veldhof, Divine Ediebah, Peter Staehr, Wojciech Zasada, Krzysztof P Malinowski, Grzegorz L Kaluza, Patrick W Serruys
OBJECTIVES: This study investigated the vasomotor response to nitroglycerine (NTG) up to 5 years after ABSORB implantation. BACKGROUND: There are no data regarding long-term vasomotor response after everolimus-eluting bioresorbable vascular scaffold ABSORB implantation. METHODS: We performed quantitative coronary angiography of the scaffolded and proximal and distal adjacent segments of patients from ABSORB Cohort B study before and after 200 μg of intracoronary NTG at 2, 3, and 5 years of follow-up...
April 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28427593/economic-outcomes-of-bioresorbable%C3%A2-vascular-scaffolds-versus%C3%A2-everolimus-eluting-stents-in-patients%C3%A2-undergoing-percutaneous-coronary-intervention-1-year-results-from-the-absorb%C3%A2-iii-trial
#10
Suzanne J Baron, Yang Lei, Khaja Chinnakondepalli, Katherine Vilain, Elizabeth A Magnuson, Dean J Kereiakes, Stephen G Ellis, Gregg W Stone, David J Cohen
OBJECTIVES: The purpose of this study was to evaluate the economic impact of the Absorb bioresorbable vascular scaffold compared with the Xience everolimus-eluting stent in patients undergoing percutaneous coronary intervention. BACKGROUND: The ABSORB III trial (Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease) demonstrated that the Absorb scaffold was noninferior to the Xience stent with respect to target lesion failure at 1 year. Whether health care costs differ between the Absorb scaffold and the Xience stent is unknown...
April 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28424439/management-of-immediate-partial-bioresorbable-vascular-scaffold-stent-thrombosis
#11
Ziad Said Dahdouh, Bahaa M Fadel, Hani Al Sergani, Jehad Al Buraiki, Gilles Grollier
Bioresorbable vascular scaffold (BVS) stents have been proposed recently as an elegant technique for treatment of coronary artery disease. However, perspective that these "dissolvable" stents will replace conventional metallic stents in broad spectrum of clinical conditions and patient categories in the near future has been moderated by non-negligible incidence of stent thrombosis (ST). Mechanical factors, such as strut thickness and malapposition have been implicated in increased risk of BVS ST. Presently described is case of immediate partial BVS ST in a young male related to technical procedural problem, rather than mechanical problem...
March 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28421591/-full-plastic-jacket-reconstruction-of-18-cm-of-coronary-arteries-with-bioresorbable-vascular-scaffolds-in-a-young-patient-with-st-elevation-myocardial-infarction-and-multivessel-disease
#12
Andrea Denegri, Antonio Halais Frangieh, Fabrizio D'Ascenzo, Jelena Rima Ghadri, Fabian Nietlispach, Christian Templin
No abstract text is available yet for this article.
2017: Cardiology Journal
https://www.readbyqxmd.com/read/28419789/overlapping-bioresorbable-scaffolds-seems-safe-for-now
#13
EDITORIAL
Jorge A Belardi, Mariano Albertal
Overlapping permanent scaffolds carries a long-term risk of target vessel failure due to late malapposition and the development of neoatherosclerosis. Potentially, overlapping bioresorbable scaffold (BRS) may lead to lower long-term risk. The GHOST-EU registry reported similar short- and mid-term risks in patients with and without BRS overlap. Larger size studies with longer follow-up are needed to confirm the safety of BRS overlap.
April 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28415397/surface-modified-bioresorbable-electrospun-scaffolds-for-improving-hemocompatibility-of-vascular-grafts
#14
Pablo C Caracciolo, María Isabel Rial-Hermida, Florencia Montini-Ballarin, Gustavo A Abraham, Angel Concheiro, Carmen Alvarez-Lorenzo
The replacement of small-diameter vessels is one of the main challenges in tissue engineering. Moreover, the surface modification of small-diameter vascular grafts (SDVG) is a key factor in the success of the therapy due to their increased thrombogenicity and infection susceptibility caused by the lack of a functional endothelium. In this work, electrospun scaffolds were prepared from blends of poly(L-lactic acid) (PLLA) and segmented polyurethane (PHD) with a composition designed to perform as SDVG inner layer...
June 1, 2017: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/28412390/first-generation-bioresorbable-vascular-scaffolds-disappearing-stents-or-disappearing-evidence
#15
EDITORIAL
Sripal Bangalore, Elazer R Edelman, Deepak L Bhatt
No abstract text is available yet for this article.
April 12, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28412389/everolimus-eluting-bioresorbable-scaffolds-versus-metallic-everolimus-eluting-stents-meta-analysis-of-randomized-controlled-trials
#16
Sabato Sorrentino, Gennaro Giustino, Roxana Mehran, Anapoorna S Kini, Samin K Sharma, Michela Faggioni, Serdar Farhan, Birgit Vogel, Ciro Indolfi, George D Dangas
BACKGROUND: Recent evidence suggests that bioresorbable vascular scaffolds (BVS) are associated with an excess of thrombotic complications compared with metallic everolimus-eluting stents (EES). OBJECTIVE: We sought to investigate the comparative effectiveness of the FDA approved Absorb BVS versus metallic EES in patients undergoing percutaneous coronary intervention at longest available follow-up. METHODS: We searched MEDLINE, Scopus and web sources for randomized trials comparing the BVS and EES...
April 12, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28408454/bioresorbable-scaffold-the-emerging-reality-and-future-directions
#17
REVIEW
Yohei Sotomi, Yoshinobu Onuma, Carlos Collet, Erhan Tenekecioglu, Renu Virmani, Neal S Kleiman, Patrick W Serruys
In the era of drug-eluting stents, large-scale randomized trials and all-comer registries have shown excellent clinical results. However, even the latest-generation drug-eluting stent has not managed to address all the limitations of permanent metallic coronary stents, such as the risks of target lesion revascularization, neoatherosclerosis, preclusion of late lumen enlargement, and the lack of reactive vasomotion. Furthermore, the risk of very late stent, although substantially reduced with newer-generation drug-eluting stent, still remains...
April 14, 2017: Circulation Research
https://www.readbyqxmd.com/read/28406183/interventional-cardiology-increased-risk-of-stent-thrombosis-with-bioresorbable-scaffolds
#18
Gregory B Lim
No abstract text is available yet for this article.
April 13, 2017: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/28402239/device-thrombosis-with-bioresorbable-scaffolds
#19
Debabrata Mukherjee
No abstract text is available yet for this article.
March 29, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28402237/bioresorbable-scaffolds-versus-metallic-stents-in-routine-pci
#20
Joanna J Wykrzykowska, Robin P Kraak, Sjoerd H Hofma, Rene J van der Schaaf, E Karin Arkenbout, Alexander J IJsselmuiden, Joëlle Elias, Ivo M van Dongen, Ruben Y G Tijssen, Karel T Koch, Jan Baan, M Marije Vis, Robbert J de Winter, Jan J Piek, Jan G P Tijssen, Jose P S Henriques
Background Bioresorbable vascular scaffolds were developed to overcome the shortcomings of drug-eluting stents in percutaneous coronary intervention (PCI). We performed an investigator-initiated, randomized trial to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in the context of routine clinical practice. Methods We randomly assigned 1845 patients undergoing PCI to receive either a bioresorbable vascular scaffold (924 patients) or a metallic stent (921 patients)...
March 29, 2017: New England Journal of Medicine
keyword
keyword
77647
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"